PredicineCAREā¢
Use
PredicineCAREā¢ provides important insights into a tumorās genomic landscape through blood, urine, and tissue. It analyzes tumor-associated genetic aberrations to provide comprehensive molecular insights into a patientās tumor biology, helping to determine whether targeted therapies are viable treatment options. The assay targets clinically actionable genes that are directly linked to specific cancers, enabling informed patient care and facilitating clinical trials.
Special Instructions
Not provided.
Limitations
PredicineCAREā¢ is a pan-cancer NGS assay with specific limitations on the reportable genomic alterations, which include single nucleotide variants (SNVs), insertions, deletions, copy number variations (CNVs), selected fusions, and homologous recombination deficiencies (HRD). Performance claims such as sensitivity of VAF detection are validated under laboratory conditions and may vary according to sample type and biological variability. Not all genomic alterations may be detectable due to assay design constraints, particularly in low-quality or suboptimal samples.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
6-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
4-10 mL
Minimum Volume
Not provided
Collection Instructions
Requires two tubes of 10mL blood for CLIA validation.